]>
IRCT20221220056873N1 IRCT 2023-04-18 Gorgan University of Medical Sciences Study on effect of Aspirin on permanent hemodialysis catheters patency rate Study on the effect of Aspirin on patency rate of permanent hemodialysis catheters in ESRD patients 2023-04-17 anticipated 74 Complete https://irct.ir/trial/69280 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Allocation of samples to groups by random four block method with permutations (AABB-ABAB-ABBA-BABA-BAAB-BBAA) where the letter A represents the intervention group and B represents the control group. Each of the blocks is given a code from 1 to 6, and the researcher randomly selects a number from 1 to 6 and corresponding to the extracted code of the selected block and corresponding to the permutations of the selected block of samples will be assigned to two groups. 3 end stage renal disease. Intervention 1: Intervention group: Oral aspirin 80 milligram tablet (from Jalinous company) will be taken daily for 1 year after right jugular permanent catheter placement, and the patency of the patient's catheter is evaluated by a checklist in two 6-month intervals from the start of use. Intervention 2: Control group: Patients with right jugular permanent hemodialysis catheter, who do not receive any medication in the period of one year, and like the intervention group, are evaluated by the checklist in two intervals of 6 months in terms of the correct functioning (patency) of the catheter. Yes - There is a plan to make this available What will be shared: All of the study's data will be available after deidentification When: The access period starts one year after publication To whom: data would be available for all researchers working in academic institutions and businesses Conditions: There is no specific limitation. Where to obtain: Dr Mohammad Farshad Zeinali Baghini, mobile: 09190257085, Email: mfzb0731@gmail.com How to obtain: After sending the request and explaining the reason for the request and the subject to be studied, the data will be provided to the requester as soon as possible. Comments:
public Mohammad Farshad Zeinali Baghini
5azar hospital, 5azar street
Gorgan Iran (Islamic Republic of) 4917763681 +98 21 2247 5984 Mfzb0731@gmail.com Gorgan University of Medical Sciences scientific Mohammad farshad Zeinali baghini
5azar hospital, 5azar street
Gorgan Iran (Islamic Republic of) 4917763681 +98 21 2247 5984 Mfzb0731@gmail.com Gorgan University of Medical Sciences Iran (Islamic Republic of) End stage kidney disease(ESRD) patients No history of psychiatric illness Consent to take the medication Right jugular permanent hemodialysis catheter Ability to communicate socially no limit no limit Both Previous right jugular catheter Bleeding disorders history N18.5 Chronic kidney disease, stage 5 Treatment - Drugs N/A Intervention group: Oral aspirin 80 milligram tablet (from Jalinous company) will be taken daily for 1 year after right jugular permanent catheter placement, and the patency of the patient's catheter is evaluated by a checklist in two 6-month intervals from the start of use. Control group: Patients with right jugular permanent hemodialysis catheter, who do not receive any medication in the period of one year, and like the intervention group, are evaluated by the checklist in two intervals of 6 months in terms of the correct functioning (patency) of the catheter. Permanent hemodialysis catheter patency rate. Timepoint: Evaluating the catheters patency 6 and 12 months after the placement and aspirin prophylaxis. Method of measurement: The criterion for the proper functioning catheter is patients complete hemodialysis session using 200 cc per minute speed, which is confirmed by the complete dialysis checklist. Gorgan University of Medical Sciences Approved 2023-01-25 Ethics committee of golestan university of medical sciences Surgery department, 5azar hospital, 5azar street Gorgan Golestan Iran (Islamic Republic of)